H.C. Wainwright raised the firm’s price target on Trevi Therapeutics (TRVI) to $7.50 from $6 and keeps a Buy rating on the shares after the company said the planned sample size re-estimation for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough requires no change to the current sample size for the study, which the firm calls a “best-case outcome.” Topline CORAL data remain on track for the first half of 2025 and the firm calls the announcement “an unequivocal and material positive for investor risk-perception and optimism around Trevi heading into upcoming data catalysts.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRVI:
- Trevi Therapeutics provides update on Phase 2b trial of Haduvio in IPF
- Trevi Therapeutics price target raised to $9 from $8 at JonesResearch
- Trevi Therapeutics selloff on data unwarranted, says H.C. Wainwright
- Trevi Therapeutics announces results from HAP study of oral nalbuphine
- Trevi Therapeutics Reports Q3 2024 Progress and Financials
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
